- Home
- SUZ vs BMRN Comparison
SUZ vs BMRN Comparison
Compare SUZ & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUZ
- BMRN
- Stock Information
- Founded
- SUZ 1924
- BMRN 1996
- Country
- SUZ Brazil
- BMRN United States
- Employees
- SUZ N/A
- BMRN N/A
- Industry
- SUZ Paper
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SUZ Basic Materials
- BMRN Health Care
- Exchange
- SUZ Nasdaq
- BMRN Nasdaq
- Market Cap
- SUZ 11.6B
- BMRN 12.1B
- IPO Year
- SUZ N/A
- BMRN 1999
- Fundamental
- Price
- SUZ $9.57
- BMRN $55.24
- Analyst Decision
- SUZ
- BMRN Buy
- Analyst Count
- SUZ 0
- BMRN 22
- Target Price
- SUZ N/A
- BMRN $93.43
- AVG Volume (30 Days)
- SUZ 2.1M
- BMRN 2.3M
- Earning Date
- SUZ 08-07-2025
- BMRN 08-04-2025
- Dividend Yield
- SUZ 2.81%
- BMRN N/A
- EPS Growth
- SUZ N/A
- BMRN 152.82
- EPS
- SUZ N/A
- BMRN 2.71
- Revenue
- SUZ $8,633,051,515.00
- BMRN $2,950,227,000.00
- Revenue This Year
- SUZ $17.17
- BMRN $12.23
- Revenue Next Year
- SUZ $9.27
- BMRN $9.99
- P/E Ratio
- SUZ N/A
- BMRN $20.33
- Revenue Growth
- SUZ 30.47
- BMRN 19.36
- 52 Week Low
- SUZ $8.41
- BMRN $52.93
- 52 Week High
- SUZ $10.98
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- SUZ 56.21
- BMRN 36.08
- Support Level
- SUZ $9.44
- BMRN $55.15
- Resistance Level
- SUZ $9.91
- BMRN $58.17
- Average True Range (ATR)
- SUZ 0.20
- BMRN 1.39
- MACD
- SUZ 0.04
- BMRN -0.01
- Stochastic Oscillator
- SUZ 72.69
- BMRN 18.89
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.